Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis - 19/12/24
Abstract |
Background |
Risk factors and the temporal relationship between atopic dermatitis (AD) and atopic march remain understudied.
Objective |
Determine risk factors for atopic march in early-onset AD patients and the temporality between AD and atopic march.
Methods |
We used the MarketScan Research Database for our retrospective cohort analysis from 2010 to 2018, comparing infants diagnosed with AD before age 1 with controls without early-onset AD. Primary outcomes were hazard ratios (HRs) for the development of asthma, allergic rhinitis, and food allergy.
Results |
Compared to 55,174 controls, higher proportions of the 27,228 AD patients developed asthma (19.21% vs 8.65%, P < .001), allergic rhinitis (28.27% vs 12.62%, P < .001), food allergy (16.00% vs 2.27%, P < .001), and all atopic triad conditions (10.69% vs 0.71%, P < .001). Among AD patients, higher proportions developed the atopic triad if they were male (HR 1.66, 95% confidence interval [1.45-1.90]), had severe disease (HR 3.16, [2.77-3.60]), or had family atopy history (HR > 3.40, P < .001 for all comparisons). Among AD patients, 20.1% developed allergic rhinitis.
Limitations |
Our study was based on health care claims data.
Conclusion |
Early-onset AD is associated with higher rates of developing atopic march conditions compared to controls. Particular attention should be paid toward risk factors and atopic march screening in early-onset AD patients.
El texto completo de este artículo está disponible en PDF.Key words : allergic, atopic dermatitis, atopic march, eczema, pediatric
Abbreviations used : AD, C-section, HR, ICD
Esquema
Drs Choi and Deng designates co-first authors with equal contribution. |
|
Drs Drucker and Kwatra designates co-senior authors. |
|
Funding sources: This work was funded by Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of Pfizer. No sponsor or funding organization was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
|
Patient consent: Not applicable. |
|
IRB approval status: Waived. |
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?